Monday, May 1, 2023
UroGen Pharma jumps amid takeover speculation
Urogen Pharma (URGN) rose 8% amid takeover speculation for the biotech firm focused on bladder cancer.Urogen (URGN) is said to have hired advisors Centerview Partners after receiving a takeover offer for $17 a share, according to a Street Insider report, which cited an unidentified source. The bank is said to be conducting a sales process with final bids due shortly.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.